Tango Therapeutics, Inc. filed 4 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-08-06. Between them they name 5 people, with 3 appointments and 2 departures. Each change below is quoted from the filing and linked to it.
Every change, newest first
Reported
Consistent with the terms of the Employment Agreement, Dr. Weber is deemed to have resigned from all officer and board member positions, including as a member of Company's board of directors (the "Board") upon the termination of Dr. Weber's employment.
Appointed: Robert Azelby, Director, effective 2026-06-19
Effective June 19, 2026, the Board appointed Robert Azelby as a director of the Company to fill the newly created vacancy on the Board resulting from the increase to the board size.
Departing: Alexis Borisy, Lead Independent Director, effective 2026-05-13
(b) Resignation of Alexis Borisy On May 12, 2026, Alexis Borisy resigned from the Company's Board of Directors (the "Board"), as Lead Independent Director of the Board, and as the Chairperson of the Compensation Committee of the Board (the "Compensation Committee") and as a member thereof, in each case effective as of May 13, 2026.
Departing: Kanishka Pothula, effective 2026-05-13
Resignation of Kanishka Pothula Also on May 12, 2026, Kanishka Pothula resigned from the Board and as a member of the Nominating and Corporate Governance Committee of the Board (the "NCG Committee"), in each case effective as of May 13, 2026.
Appointed: Matthew Gall, Chief Financial Officer, effective 2026-04-15
On April 10, 2026, the Board appointed Matthew Gall, MBA, 49, as the Company's Chief Financial Officer and principal financial officer effective as of April 15, 2026.
Appointed: Jessica Newcomb, effective 2026-04-15
On April 10, 2026, the Board appointed Jessica Newcomb, 40, to serve as the Company's principal accounting officer effective as of April 15, 2026.
Find people with the same kind of experience as the Director at Tango Therapeutics, Inc., with the record behind each one.
Find candidates like Director at Tango Therapeutics, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Tango Therapeutics, Inc. is in the news or changes leadership.
Get an alert when Tango Therapeutics, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Tango Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.